ArticleBMC medical research methodology2026
Capacity building at an Australian regional clinical trials unit: determinants of growth and correlation with a capability framework.
Article in BMC medical research methodology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExpanding the capacity for clinical trials in regional/nonmetropolitan locations will increase accessibility for patients who live remotely, however there are limited studies on the growth of regional clinical trials units over time. This study aims to explore the status of the growth of a regional Australian clinical trial unit between 2011 and 2022, utilising a recently published clinical trial capability framework.
methodsAn evaluation of a regional clinical trial unit in Victoria, Australia, between 2011 and 2022 was conducted to objectively describe growth, including the number of trials, number of patients and number of principal investigators (PIs). We used an objective capability framework published by Woollett et al. (2023). The framework uses a maturity model applied across several domains. Descriptive statistics are reported as totals and means. Scatter plots, pairwise correlations and Bland-Altman adjustments for trends were computed to show correlations and agreements between the framework average score and objective measures of the clinical trials between 2011 and 2022.
resultsThe number of clinical trials active in 2011 and 2022 were n = 4 and n = 70, respectively. Across all domains, the Grampians Health Clinical Trials Unit was assessed as 'established' in 2011, whereas the trial unit was considered 'high performing' in 2022. The framework capability score correlated well with the number of PIs per year (r (10) = 0.9, p < 0.001), the number of open trials per year (r (10) = 0.9, p < 0.001), and the number of patients (r (10) = 0.8, p < 0.001). The key contributors to growth identified were organisational support and infrastructure. Growth was largely driven by oncology trials.
conclusionSignificant growth was observed for a regional clinical trial unit across a decade. The framework score strongly correlated with objective clinical trial data. Understanding the growth of clinical trial units in nonmetropolitan areas is essential for developing the capacity of clinical trials in regional and rural areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.